A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Phase 1
315
about 5.5 years
18+
25 sites in AL, CA, IA +5
About this study
Researchers are testing the safety of a drug called PF-08046054/SGN-PDL1V alone and with pembrolizumab in people with solid tumors. The trial will also trial the side effects of this drug.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take PF-08046054
- 2.Take pembrolizumab
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
pembrolizumab (Immune checkpoint inhibitor; blocks PD-1 to boost T-cell attack on cancer)
infusion
Primary: Number of participants with adverse events (AEs), Number of participants with dose-limiting toxicities (DLTs), Number of participants with laboratory abnormalities
Secondary: Confirmed objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) by investigator assessment, Duration of objective response (DOR) per RECIST v1.1 by investigator assessment, Incidence of anti-drug antibodies (ADAs), Overall survival (OS), PK parameter - Maximum concentration (Cmax), PK parameter - Trough concentration (Ctrough), Pharmacokinetic (PK) parameter - Area under the concentration-time curve (AUC), Progression-free survival (PFS) per RECIST v1.1 by investigator assessment
Oncology